Patent · US Active

Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing

US11147827B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

VANDERBILT UNIVERSITY · US

Inventors

Craig L. Duvall · Nashville, US
Samantha M. Sarett · Nashville, US
Thomas A. Werfel · Nashville, US

Key dates

Filing date	Aug 7, 2017
Grant date	Oct 19, 2021
Priority date	—
Expiry date	Aug 7, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.